

10/588542

IAP11 Rec'd PCT/PTO 07 AUG 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Takayuki HIDA et al. : **Mail Stop: PCT**  
Serial No. NEW : Attorney Docket No. 2006\_1298A  
Filed August 7, 2006 :  
:

SCREENING METHOD  
[Corresponding to PCT/JP05/001887  
Filed February 9, 2005]

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- each U.S. Patent and U.S. Patent application publication;
- each reference previously cited in the international application PCT/\_\_\_\_\_; and/or
- each reference previously cited in prior parent application Serial No. \_\_\_\_\_;

1a.  This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b.  This Information Disclosure Statement is submitted after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1)  the certification of paragraph 2 below is provided, or

(2)  the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c.  This Information Disclosure Statement is submitted: after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and**

**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

a.  that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b.  that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3.  Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

10/588512  
IAP11 Rec'd PCT/PTO 07 AUG 2006

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:

- a. [ ] a full or partial English language translation submitted herewith,
- b. [ ] a foreign patent office search report (in the English language) submitted herewith,
- c. [ ] the concise explanation contained in the specification of the present application at page,
- d. [ ] the concise explanation set forth in the attached English language abstract,
- e. [ ] the concise explanation set forth below or on a separate sheet attached to the reference:

5. [X] International Search Report citing one or more of the references is enclosed.

Respectfully submitted,

Takayuki HIDA et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/jmj  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
August 7, 2006

10/588242  
APR 11 2006 PCT/PTO 07 AUG 2006

FORM PTO 1449 (modified)		ATTY DOCKET NO. 2006_1298A	SERIAL NO. NEW
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		APPLICANT Takayuki HIDA et al.	
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		FILING DATE August 7, 2006	GROUP
Date Submitted to PTO: August 7, 2006			

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AJ	2004/112575 A2	12/2004	WO			
	AK	03/030930 A1	4/2003	WO			
	AL						
	AM						
	AN						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	C. Liu et al., Identification of relaxin-3/ INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135, 2003, J.Biol.Chem., 278(50), p.50754-64.
	AP	C. Liu et al., Identification of relaxin-3/ INSL7 as a ligand for GPCR142, 2003, J.Biol.Chem., 278(50), p. 50765-70.
	AQ	R.A. Bathgate et al., Relaxin: new peptides, receptors and novel actions, 2003, Trends Endocrinol Metab, 14(5), p. 207-13.
	AR	H. KIZAWA et al., Production of recombinant human relaxin 3 in AtT20 cells, 2003, Regul. Pept., 113(1-3), pages 79 to 84.
	AS	S. SUDO et al., H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2, 2003, J. Biol.Chem., 278(10), p. 7855-62.
	AT	C.S. Samuel et al., Physiological or pathological-a role for relaxin in the cardiovascular system?, 2003, Curr.Opin. Pharmacol., 3(2), p. 152-8.

EXAMINER

DATE CONSIDERED